Sweden
· Delayed Price · Currency is SEK IBT.B Company Description
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden.
The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants.
It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections.
The company was incorporated in 2011 and is based in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Staffan Stromberg |
Contact Details
Address: Bryggargatan 10 Stockholm, 111 21 Sweden | |
| Phone | 46 7 62 19 37 38 |
| Website | ibtherapeutics.com |
Stock Details
| Ticker Symbol | IBT.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0008015259 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Staffan Stromberg Ph.D. | Chief Executive Officer |
| Maria Ekdahl | Chief Financial Officer |
| Anders Kronström M.B.A., M.S. | Chief Operating Officer |
| Dr. Thomas J. Schnitzer M.D., Ph.D. | Chief Scientific Officer |
| Sanjiv Sharma M.B.A. | Head of Medical Affairs |
| Prof. Jonas Rastad M.D., Ph.D. | Chief Medical Officer |